China Animal Vaccine Industry Report, 2016-2020
  • June 2016
  • Hard Copy
  • USD $2,700
  • Pages:156
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM077
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen slower growth due to quality safety, high maturity and other factors, while the animal vaccine markets in emerging countries including China have developed rapidly.

The Chinese animal vaccine market size grew from RMB1.4 billion in 2004 to RMB14.0 billion in 2014 at a high rate of 25.9%, and is expected to hit around RMB16.9 billion in 2015, a year-on-year increase of 20.7%.

In China, animal vaccines fall into two categories: 1. Epidemic disease vaccines subject to national compulsory immunization programme (compulsory immunization vaccines include highly pathogenic avian influenza vaccine, foot-and-mouth disease vaccine, highly pathogenic PRRS vaccine, swine fever vaccine, and PPR vaccine in Xinjiang and Tibet); 2. Epidemic disease vaccines beyond national compulsory immunization programme (non-compulsory immunization vaccines). As the problems like low price and low quality caused by the system of purchasing by invitation to bid have greatly impacted the development of livestock and poultry breeding in China, the government has been piloting reform of the tendering system in multiple regions, planning to advance the marketization of vaccines through direct subsidies to farmers.

Large breeding companies, out of overall consideration based on economic benefits, are increasingly inclined to buy high-quality market-oriented vaccines which are 5-15 times as expensive as vaccines purchased under policy. Hence, the Chinese animal vaccine market size is expected to grow significantly in the future, reaching RMB41.2 billion in 2020.

Despite a large number of animal vaccine companies (about 100) in China, the industry is less concentrated. In 2015, China Animal Husbandry Industry Co., Ltd. (CAHIC) held the largest share (7.4%) of the Chinese animal vaccine market in 2015, followed by Jinyu Bio-technology (7.2%), Qingdao Yebio Biological Engineering (5.0%), Xinjiang Tecon Animal Husbandry Bio-Technology (4.6%), Pulike Biological Engineering (2.8%), and Tianjin Ringpu Bio-technology (2.8%).

Although the Chinese animal vaccine market is primarily controlled by domestic companies with a share of 90% or so, the high-end vaccine market, such as pet vaccines, is occupied by foreign brands including Zoetis (formerly Pfizer’s animal health division), Fort Dodge, Intervet, Merial, and BoehringerIngelheim. These foreign players not only directly sell vaccines in China but also have been increasing their investment in the country.

In 2014, the animal vaccine manufacturing base, with total investment of EUR55.5 million and jointly founded by BoehringerIngelheim and Taizhou China Medical City, started construction. Some pig vaccines will be first commercialized in the China Medical City after the manufacturing base is completed in 2016. Intervet Holding BV and CAHIC signed a cooperation agreement in 2015, planning to jointly explore domestic and foreign markets and enhance competitiveness.

However, Chinese local animal vaccine companies are also scaling up efforts for research and development, making their presence in high-end vaccines and expanding varieties of vaccines. There were 25 kinds of registered animal vaccines in China in 2015, a year-on-year growth of 78.6%, including 10 kinds of pig vaccines, 10 kinds of poultry vaccines, and 5 kinds of other animal vaccines like Mink Hemorrhagic Pneumonia Bivalent Vaccine, Inactivated (Serotype G, Stain WD005 + Serotype B, Stain DL007) and Turbot EdwardsiellatardaVaccine, Live (Strain EIBAV1).

Moreover, great progress has been made in pet vaccines. Rabies vaccines, inactivated produced by Pulike Biological Engineering, Tianjin Ringpu Bio-technology, and Shanghai Hile Bio-Technology are expected to be approved and go on the market at the end of 2016 or in 2017.

Animal Vaccine Revenue of Major Animal Vaccine Companies in China, 2014-2015

China Animal Vaccine Industry Report, 2016-2020 by ResearchInChina highlights the followings:
20120114.gifGlobal animal vaccine industry (market size/structure, competitive landscape, etc.);
20120114.gifChina’s animal vaccine industry (market size/structure, competitive landscape, import/export, etc.);
20120114.gifChina’s animal vaccine industry (policy environment, social environment, downstream demand, etc.);
20120114.gifMarket segments (pig vaccines, poultry vaccines) in China (market size, competitive landscape, etc.);
20120114.gif16 Chinese animal vaccine producers (operation, animal vaccine business, forecast & outlook, etc.);
20120114.gifChinese animal vaccine market and market segments (market size/structure forecast) during 2016-2020.

1. Overview of Animal Vaccine
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Status Quo of Animal Vaccine Industry
2.1 Global Market
2.1.1 Market Size
2.1.2 Market Structure
2.1.3 Competitive Landscape
2.2 Chinese Market
2.2.1 Market Size
2.2.2 Market Structure
2.2.3 Import and Export
2.2.4 Profit
2.2.5 Entry Barriers
2.2.6 Competitive Landscape
2.2.7 Trends

3. Development Environment for China Animal Vaccine Industry
3.1 Policy Environment
3.1.1 Major Policies
3.1.2 Tendering System for Compulsory Immunization Vaccine
3.2 Social Environment
3.2.1 Stable Development of Farming Industry
3.2.2 Large-scale Farming Becomes a Trend
3.2.3 Frequent Outbreaks of Animal Epidemics

4. Chinese Animal Vaccine Industry Segments
4.1 Governmental Mandatory Vaccine
4.1.1 FMD Vaccine
4.1.2 Bird Flu Vaccine
4.1.3 PRRS Vaccine
4.1.4 Swine Fever Vaccine
4.2 Market-oriented Vaccine
4.2.1 PCV Vaccine
4.2.2 Newcastle Disease Vaccine
4.3 Pet Vaccine

5 Key Enterprises
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D
5.1.6 Animal Vaccine Business
5.1.7 Forecast and Outlook
5.2 Jinyu Bio-technology
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D
5.2.6 Animal Vaccine Business
5.2.7 Forecast and Outlook
5.3 Tecon
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D
5.3.6 Clients and Suppliers
5.3.7 Animal Vaccine Business
5.3.8 Forecast and Outlook
5.4 Tech-bank
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D
5.4.6 Animal Vaccine Business
5.4.7 Forecast and Outlook
5.5 ShenghuaBiok
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D
5.5.6 Animal Vaccine Business
5.5.7 Forecast and Outlook
5.6 Ringpu Bio-technology
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 R&D
5.6.6 Animal Vaccine Business
5.6.7 Forecast and Outlook
5.7 Wens Dahuanong
5.7.1 Profile
5.7.2 Operation
5.7.3 Revenue Structure
5.7.4 Gross Margin
5.7.5 R&D
5.7.6 Animal Vaccine Business
5.7.7 Forecast and Outlook
5.8 Hile Bio
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 Gross Margin
5.8.5 R&D
5.8.6 Animal Vaccine Business
5.8.7 Forecast and Outlook
5.9 Pulike
5.9.1 Profile
5.9.2 Operation
5.9.3 Revenue Structure
5.9.4 Gross Margin
5.9.5 R&D
5.9.6 Animal Vaccine Business
5.9.7 Forecast and Outlook
5.10 Chopper
5.10.1 Profile
5.10.2 Operation
5.10.3 Revenue Structure
5.10.4 Gross Margin
5.10.5 R&D
5.10.6 Clients and Suppliers
5.10.7 Animal Vaccine Business
5.11 Other Enterprises
5.11.1 Yikang Biological
5.11.2 Weike Biotechnology
5.11.3 Guangdong Winsun Bio-pharmaceutical
5.11.4 Shenlian Biotechnology
5.11.5 Keqian Biology
5.11.6 Nannong Hi-Tech

6. Summary and Forecast
6.1 Summary
6.2 Development Forecast
6.2.1 Swine Vaccine
6.2.2 Poultry Vaccine
6.2.3 Cattle and Sheep Vaccine
6.2.4 Pet Vaccine
Classification of Animal Health Products
Animal Vaccine Types (by Constituent and Feature) and Characteristics
Animal Vaccine Industry Chain
Classification of Animal Epidemics in China
Global Animal Vaccine Market Size, 2008-2020E
Global Animal Vaccine Consumption Structure, 2015
Major M&A Events in Global Animal Health Industry, 2005-2015
Profile of Global Animal Health Products Giants
Development Process of Chinese Compulsory Vaccination Policies
Chinese Animal Vaccine Market Size, 2004-2015
China’s Animal Vaccine Net Import Value and Dependence on Export, 2008-2015
China’s Animal Vaccine Product Structure (by Animal Species), 2010-2015
Newly-approved Pig/Poultry Vaccines in China, 2015
China’s Animal Vaccine Import and Export Volume, 2009-2015
China’s Average Animal Vaccine Import and Export Prices, 2009-2015
China’s Animal Vaccine Import Sources (by Import Value), 2015
China’s Animal Vaccine Export Destinations (by Export Value), 2015
Main Regions Which Import Animal Vaccines and Their Share in Import Volume in China, 2015
Main Regions Which Export Animal Vaccines and Their Share in Export Volume in China, 2015
Gross Margin of Animal Vaccine Business of Major Listed Animal Vaccine Companies in China, 2011-2015
Barriers to Entry into Animal Vaccine Industry in China
Major Chinese Animal Vaccine Manufacturers, 2015
Competitive Landscape of China Animal Vaccine Industry, 2015
Proportion of Large-scale Pig Breeding in China, 2006-2015
Vaccines’ Percentage of Total Costs in Different Breeding Sizes
Epidemic Prevention Expenses for Live Pigs Bred on a Large Scale and YoY in China, 2005-2013
Gap between Chinese Vaccine Production Process and International Advanced Level
Sino-foreign Joint Animal Vaccine Enterprises, 1990-2015
Major Polices on China Animal Vaccine Industry, 2010-2015
Compulsory Immunization Plan of Animal Epidemics in China, 2016
Animal Diseases worth Priority Prevention in China, 2012-2020
Defects of China’s Compulsory Immunization Tender System
Direction for China’s Compulsory Immunization Tender System Reform
Output of Meat, Eggs and Milk in China, 2009-2015
China’s Meat Product Structure (by Output), 2011-2015
Farming Scale Degree in China, 2010-2020E
Overview of Common Animal Epidemics in China
China’s Animal Vaccine Market Structure (by Sales Method)
Usage of Vaccines by Small and Medium-sized Live Pig Farmers by Product in China (%)
Winning Prices of Main Animal Vaccines in China, 2015
Competitive Landscape of Main Compulsory Immunization Vaccine Markets in China, 2015
Market Structure of Animal Vaccines Subject to National Compulsory Immunization Programme, 2015
Potential Scale of Chinese Foot-and-Mouth Disease Vaccine Market
Performance Comparison between Swine Fever Vaccines in China
Classification and Market Conditions of Market-oriented Vaccines in China
Market Capacity of Some Non-compulsory Vaccines in China, 2015
Market Prices of PCV Vaccines in China by Enterprise, 2015
Pet Vaccine Suppliers in Chinese Market and Their Products
R&D of Main Pet Vaccines in China by the end of Apr 2016
CAHIC’s Revenue and Net Income, 2009-2016
CAHIC’s Output, Sales Volume and Inventory, 2015 (10k ml/10k doses, ton)
CAHIC’s Revenue (by Product), 2011-2015
CAHIC’s Revenue Structure (by Product), 2011-2014
CAHIC’s Revenue (by Region), 2011-2015
CAHIC’s Revenue Structure (by Region), 2011-2015
Gross Margin of CAHIC’s Main Products, 2011-2015
CAHIC’s R & D Costs and % of Total Revenue, 2011-2015
CAHIC’s Animal Vaccine Subsidiaries and Their Products
Revenue from and Gross Margin of Veterinary Vaccines of CAHIC, 2011-2015
CAHIC’s Varieties/Output/Sales Volume of and Revenue/Net Income from Main Veterinary Vaccines, 2015
Winning Prices of CAHIC’s Veterinary Vaccines, 2015
CAHIC’s Revenue and Net Income, 2015-2020E
Jinyu Bio-technology’s Revenue and Net Income, 2009-2016
Jinyu Bio-technology’s Revenue (by Product), 2011-2015 (Unit: RMB mln)
Jinyu Bio-technology’s Revenue Structure (by Product), 2011-2015
Jinyu Bio-technology’s Revenue (by Region), 2011-2015
Jinyu Bio-technology’s Revenue Structure (by Region), 2011-2015
Gross Margin of Jinyu Bio-technology’s Main Business, 2010-2015
Jinyu Bio-technology’s R&D Costs and % of Total Revenue, 2011-2015
Animal Vaccine Subsidiaries of Jinyu Bio-technology, 2015
Jinyu Bio-technology’s Output/Sales Volume/Inventory of Main Vaccines, 2015
Jinyu Bio-technology’s Revenue from and Gross Margin of Vaccines, 2011-2015
Main Reserve Vaccines of Jinyu Bio-technology
Revenue and Net Income of JinyuBaoling, 2012-2015
Assets and Net Income of Yangzhou Uni-Bio Pharmaceutical, 2012-2015 
Jinyu Bio-technology’s Revenue and Net Income, 2015-2020E
Tecon’s Revenue and Net Income, 2009-2016
Tecon’s Revenue (by Product), 2011-2015
Tecon’s Revenue Structure (by Product), 2011-2015
Tecon’s Revenue (by Region), 2011-2015
Tecon’s Revenue Structure (by Region), 2011-2015
Gross Margin of Tecon’s Main Products, 2011-2015
Tecon’s R & D Costs and % of Total Revenue, 2011-2015
Tecon’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Tecon’s Top 5 Clients, 2015
Tecon’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2015
Name List and Procurement Contribution of Tecon’s Top 5 Suppliers, 2015
Tecon’s Animal Vaccine Production Bases and Capacity, 2015
Animal Vaccines under Research and Progress of Tecon by the end of Apr 2016
Revenue and Gross Margin of Tecon, 2011-2015
Tecon’s Revenue and Net Income, 2015-2020E
Tech-bank’s Revenue and Net Income, 2009-2015
Tech-bank’s Revenue (by Product), 2011-2015
Tech-bank’s Revenue (by Region), 2011-2015
Tech-bank’s Revenue Structure (by Region), 2011-2015
Tech-bank’s Gross Margin of Main Products, 2011-2015
Tech-bank’s R&D Costs and % of Total Revenue, 2011-2015
Revenue and Net Income of Chengdu Tech-bank, 2010-2015
Tech-bank’s Revenue and Net Income, 2015-2020E
ShenghuaBiok’s Revenue and Net Income, 2009-2015
ShenghuaBiok’s Revenue (by Product), 2011-2015
ShenghuaBiok’s Revenue Structure (by Product), 2011-2015
ShenghuaBiok’s Revenue (by Region), 2011-2013
ShenghuaBiok’s Revenue Structure (by Region), 2011-2015
Gross Margin of ShenghuaBiok’s Main Products, 2011-2015
Shenghua’s R&D Costs and % of Total Revenue, 2011-2015
Revenue and Net Income of Qingdao Yebio, 2009-2015
ShenghuaBiok’s Revenue and Net Income, 2015-2020E
Ringpu Bio-technology’s Revenue and Net Income, 2009-2016
Ringpu Bio-technology’s Revenue (by Product), 2011-2015
Ringpu Bio-technology’s Revenue Structure (by Product), 2011-2015
Ringpu Bio-technology’s Revenue (by Region), 2012-2015
Ringpu Bio-technology’s Revenue Structure (by Region), 2012-2013
Ringpu Bio-technology’s Gross Margin of Main Products, 2011-2015
Ringpu Bio-technology’s R&D Costs and % of Total Revenue, 2011-2015
Varieties of Animal Vaccines Launched of Ringpu Bio-technology, 2014-Jan 2016
Ringpu Bio-technology’s Animal Vaccine Output and Sales Volume (by Product), 2011-2015
Sales and Gross Margin of Ringpu Bio-technology’s Animal Vaccines (by Product), 2013-2015
Ringpu Bio-technology’s Animal Vaccine Subsidiaries and Their Products, 2015
Revenue and Net Income of Ringpu Bio-technology’s Animal Vaccine Subsidiaries, 2013-2015
Ringpu Bio-technology’s Revenue and Net Income, 2015-2020E
Wens Dahuanong’s Revenue and Net Income, 2009-2015
Output and Sales Volume of Wens Dahuanong’s Main Products, 2013-2014
Wens Dahuanong’s Revenue (by Product), 2011-2015
Wens Dahuanong’s Revenue Structure (by Product), 2011-2015
Wens Dahuanong’s Revenue (by Region), 2011-2014
Wens Dahuanong’s Revenue Structure (by Region), 2011-2014
Gross Margin of Wens Dahuanong’s Main Products, 2011-2015
Wens Dahuanong’s R&D Expenditure and % of Total Revenue, 2011-2015
Revenue and Gross Margin of Wens Dahuanong’s Animal Vaccine Products , 2011-2015
Output, Sales Volume and Sales-output Ratio of Wens Dahuanong’s Veterinary Biologics, 2012-2014
Wens Dahuanong’s Revenue and Net Income, 2015-2020E
Hile Bio’s Main Products
Hile Bio’s Revenue and Net Income, 2011-2016
Hile Bio’s Revenue Structure (by Product), 2011-2015
Hile Bio’s Revenue Structure (by Product), 2011-2015
Hile Bio’s Revenue (by Region), 2011-2015
Hile Bio’s Revenue Structure (by Region), 2011-2015
Gross Margin of Hile Bio’s Main Products, 2011-2015
Hile Bio’s R&D Costs and % of Total Revenue, 2011-2015
Hile Bio’s Animal Vaccines under Research and R&D Investment, 2015
Hile Bio’s Revenue Structure (by Sales Method), 2011-2015
Hile Bio’s Swine Vaccine Output,Sales Volume and Inventory, 2015
Selling Prices of Hile Bio’s Main Products, 2011-2013
Hile Bio’s Revenue and Net Income, 2015-2020E
Key Holding and Joint-stock Subsidiaries of Pulike, 2015
Pulike’s Revenue and Net Income, 2012-2016
Pulike’s Sales Model and Revenue Structure, 2014-2015
Pulike’s Revenue (by Product), 2012-2015
Pulike’s Revenue Structure (by Product), 2012-2015
Gross Margin of Pulike’s Main Products, 2012-2015
Pulike’s R&D Costs and % of Total Revenue, 2011-2015
Output, Sales Volume, and Inventory of Pulike’s Animal Vaccines, 2015
Output and Sales Volume of Pulike’s Main Animal Vaccines, 2015
Revenue and Gross Margin of Pulike, 2012-2015
Pulike’s Revenue and Net Income, 2015-2020
Chopper’s Revenue and Net Income, 2009-2013
Chopper’s Revenue (by Product), 2011-2013
Chopper’s Revenue Structure (by Product), 2011-2013
Chopper’s Revenue (by Region), 2011-2013
Chopper’s Revenue Structure (by Region), 2011-2013
Sales of Chopper's Main Vaccine Products, 2011-2013
Chopper’s R & D Costs and % of Total Revenue, 2011-2013
Chopper’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Chopper’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013
Name List and Procurement Contribution of Chopper’s Suppliers, 2013
Chopper’s Products and Clients (by Sales Method)
Chopper’s Sales Structure by Sales Method, 2011-2013
Sales of Chopper’s Main Vaccine Products, 2011-2013 (Unit: RMB mln)
Chopper’s Sales Structure by Main Vaccine Product, 2011-2013
Chopper’s Vaccine Capacity, Output and Capacity Utilization, 2011-2013
Chopper’s Vaccine Output, Sales Volume and Sales-output Ratio, 2011-2013
Average Selling Price of Chopper’s Main Vaccine Products, 2011-2013
Chopper’s Investment Plan, 2014
Yikang’s Revenue and Net Income, 2009-2011
Yikang’s Revenue (by Product), 2009-2011
Yikang’s Revenue (by Region), 2009-2011
Gross Margin of Yikang’s Main Products, 2009-2011
Yikang’s Animal Vaccine Production Lines, 2009-2011
Yikang’s Capacity, Output and Capacity Utilization, 2009-2011
Yikang’s Output, Sales Volume and Sales-output Ratio, 2009-2011
Average Selling Price of Yikang’s Main Products, 2009-2011
Yikang’s Revenue Structure (by Sales Method), 2009-2011
Animal Vaccine Revenue of Major Animal Vaccine Companies in China, 2011-2015
Chinese Animal Vaccine Market Size, 2014-2020E
Chinese Animal Vaccine Market Structure (by Animal Attributes), 2013 vs 2016E
Chinese Swine Vaccine Market Size, 2015-2020E
Chinese Poultry Vaccine Market Size, 2015-2020E
Chinese Cattle and Sheep Vaccine Market Size, 2015-2020E
Chinese Pet Vaccine Market Size, 2015-2020E

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号